Search results for: covid

Pharming Group N.V. announces the topline results from two randomized, open label, controlled, pilot clinical trials of patients hospitalized with COVID-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the 7-point WHO ordinal scale on Day 7. In the [...]

The first patient has been enrolled in a randomised, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalized with confirmed COVID-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the United States. Initially based at [...]

In its annual R&D briefing to investors CSL Limited demonstrates how the company is advancing a novel research portfolio across four strategic scientific platforms (Plasma Fractionation, Recombinant Technology, Cell and Gene Therapy, Adjuvanted Cell and Egg-based Vaccines) across six therapeutic areas (Immunology, Hematology, Respiratory, Cardiovascular and Metabolic, Transplant, Influenza Vaccines) and two businesses (CSL Behring [...]

IONIS-PKK-LRx from Ionis Pharmaceuticals, Inc. is being evaluated in an investigator-initiated Phase 2 clinical study to determine its effectiveness in reducing the severity of respiratory complications in patients with COVID-19. The trial coordinators are Fernando G. Zampieri, M.D., Ph.D., and Alexandre Biasi Cavalcanti, M.D., Hospital do Coracao (HCor Research Institute), Sao Paulo, Brazil. The study [...]

Pharming Group N.V. announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use programme of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with Ruconest (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland. As reported on 21 April [...]

The first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with Ruconest (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia at the University Hospital Basel in Basel, Switzerland. In April 2020, Pharming Group N.V. reported encouraging results [...]

Together with the COVID R&D Alliance partners AbbVie, Inc. and Amgen Inc., Takeda Pharmaceutical Co. Ltd. has enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The trial will evaluate the efficacy of a chemokine dual-receptor antagonist, a PDE4 [...]

CSL Behring has enrolled the first patient in its Phase 2 study to assess the safety and efficacy of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe respiratory distress, a leading cause of death in patients with COVID-19 related pneumonia. In this multicenter, double-blind, placebo-controlled study, approximately 124 adult patients [...]

Pharming Group N.V. sees encouraging results from five patients with confirmed COVID-19 infections hospitalized with related severe pneumonia that were treated with Ruconest (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland. Four male patients and one female patient (between 53-85 years of age) with COVID-19 and suffering from [...]

BioCryst Pharmaceuticals, Inc. has opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. The trial is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Galidesivir is an investigational broad-spectrum [...]

“The Phase 2 clinical trial for KVD900 as an on-demand oral therapy for HAE attacks remains active, but we anticipate a delay in timing of data due to the unprecedented worldwide impact of COVID-19”, says Andrew Crockett, CEO of KalVista Pharmaceuticals, Inc.: “A number of our participating physicians and clinical sites have shifted their focus [...]

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring and Takeda Pharmaceutical Company Limited to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the [...]

At the recent 2023 HAEi Regional Conference EMEA, we got to sit down with HAEi Leadership (from left), Henrik Balle Boysen, Tony Castaldo, Fiona Wardman, and Jørn Schultz-Boysen. We spoke to them about their passion for advocacy and their hopes and fears for the future. HAEi Leadership Roundtable Interview: Advocacy is Proactivity Let’s start [...]

Hi everyone, It’s hard to believe we are already getting close to celebrating a New Year! Before we talk about our plans for 2023, however, let’s reflect on the great things that happened throughout 2022. We kicked the year off with so many goals that even the Youngsters’ Community Coordinator, Nevena Tsutsumanova, thought we [...]

The first HAEi Global Leadership Workshop held in October brought HAE Member Organization leaders, the global HAE scientific community, and the pharmaceutical industry together for the first time in over four and a half years. “As the first event of its kind, we are very interested in our Member Organizations’ evaluation of the meeting,” [...]

Early in the pandemic, HAE patient Scott McCoy described his encounter with COVID-19 in a webinar for US HAEA. It was a bad news-good news story. The bad news was that McCoy had become infected with the novel coronavirus prior to vaccines being available. But the good news was that his infection did not cause [...]

By Anthony J. Castaldo, HAEi President & CEO Access to modern HAE medicines is the key to improving our community’s quality of life. HAEi’s experience working with member organizations shows that having robust and reliable real-world data is a key component winning approval for a therapy. HAEi conducts targeted, scientific based research designed to [...]

Getting back to school year routine is always a challenge after enjoying the summer months. However, for many, this fall will be the first time back in school for full days, five days a week, since March 2020. In-person school is therefore likely to be a distant memory. On top of that, COVID-19 related [...]

Plasma helps your body fight diseases, and it deserves greater recognition. Ask people who have certain rare and chronic complex diseases – they will tell you that therapies made from donated plasma help them manage conditions such as immunodeficiency disorders, hemophilia, and HAE. Plasma is a core substance within our blood and carries important cells, [...]

At the EAACI Hybrid Congress 2021, BioCryst Pharmaceuticals, Inc. announced that HAE patients who were randomized to receive 150 mg of oral, once-daily Orladeyo® (berotralstat) at the start of the APeX-2 trial had an 80 percent average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. Median attack [...]

We are very excited to share with you that we are kick-starting our Blog again! We are so happy to present Pravalika from India. She is amazing, cheerful, and very passionate about photography. This is her story from the HAEi Youngsters Blog:  Where are you from? I am Pravalika from India :-) What was [...]

– yet another virtual event Due to the uncertain situation caused by the COVID-19 pandemic, the 12th C1-Inhibitor Deficiency and Angioedema Workshop was held online on 3-6 June 2021. The command center of the workshop was the studio of Diamond Congress, with Professor Henriette Farkas and Senior Research Scientist Lilian Varga once more [...]

Showcasing the work of the 93 member countries and learning a lot of fun and interesting things along the way 341 photos in the gallery to share activities –  – visit haeday.org before 1 November 2021 to see them all! Input from the Regional Patient Advocates supporting the regions; both in writing and in [...]

At the presentation of the Takeda Pharmaceutical Company Limited financial results for the fiscal year 2020 (period ended 31 March 2021), President and CEO Christophe Weber says: “Takeda remained resilient as we operated in new ways through the COVID-19 pandemic. We maintained business continuity, ensured patient access to our medicines and safeguarded the health and well-being of [...]

The network of ACARE centers continues to grow despite the many challenges created by COVID-19.  ACARE is a joint venture with GA²LEN and HAEi that fulfills HAEi’s longstanding goal of establishing a worldwide network of accredited angioedema care centers.  In 2020 and 2021, the ACARE Network launched, hosted and aired two webinar series.  The [...]

16 May 2021 marks the 10th anniversary of the hae day :-) awareness day. For the last ten years, HAEi and its member organizations worldwide have used 16 May as a focus for raising awareness: not just on the day itself but in the weeks leading up to it.  Let’s Take the Next Step [...]

At times it can seem hard to keep track of all that has evolved in and around HAE over the years. Here is an overview – at least when it comes to the development of HAE International. 2002 Alarmed at the potential consequences of [...]

In its financial results for the third quarter of 2020 Ionis Pharmaceuticals, Inc. reports the advance in the IONIS-PKK-LRx program: Proof-of-concept data from the PKK development program in patients with HAE were reported in the New England Journal of Medicine Enrollment completed in the IONIS-PKK-LRx Phase 2 study in patients with HAE IONIS-PKK-LRx advanced into [...]